share_log

Verizon | 25-NSE: Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities (and amendment thereto)

Verizon | 25-NSE: Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities (and amendment thereto)

Verizon | 25-NSE:由交易所申报的注销已到期、已赎回、已兑付证券的通知
美股SEC公告 ·  2024/06/18 05:38

Moomoo AI 已提取核心信息

The New York Stock Exchange (NYSE) has officially notified the Securities and Exchange Commission (SEC) of its intention to delist the entire class of securities from Biodexa Pharmaceuticals Plc. The notification, which follows the provisions of Rule 12d2-2(a), states that the securities will be removed from listing and registration at the start of business on July 1, 2024. This action comes after the securities were redeemed or paid at maturity on June 18, 2024. Consequently, trading of Biodexa Pharmaceuticals' securities was suspended on the same day of redemption.
The New York Stock Exchange (NYSE) has officially notified the Securities and Exchange Commission (SEC) of its intention to delist the entire class of securities from Biodexa Pharmaceuticals Plc. The notification, which follows the provisions of Rule 12d2-2(a), states that the securities will be removed from listing and registration at the start of business on July 1, 2024. This action comes after the securities were redeemed or paid at maturity on June 18, 2024. Consequently, trading of Biodexa Pharmaceuticals' securities was suspended on the same day of redemption.
纽约证券交易所(NYSE)已正式通知证券交易委员会(SEC)其打算从Biodexa Pharmaceuticals Plc删除所有证券类别。通知遵循Rule 12d2-2(a)的规定,指出这些证券将在2024年7月1日营业开始时从上市和登记中被移除。此举是在这些证券于2024年6月18日赎回或到期支付后进行的。因此,Biodexa Pharmaceuticals公司证券的交易也在赎回当天暂停。
纽约证券交易所(NYSE)已正式通知证券交易委员会(SEC)其打算从Biodexa Pharmaceuticals Plc删除所有证券类别。通知遵循Rule 12d2-2(a)的规定,指出这些证券将在2024年7月1日营业开始时从上市和登记中被移除。此举是在这些证券于2024年6月18日赎回或到期支付后进行的。因此,Biodexa Pharmaceuticals公司证券的交易也在赎回当天暂停。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息